TRANE-TECHNOLOGIES
17.8.2020 06:32:12 CEST | Business Wire | Press release
Global climate innovator Trane Technologies (NYSE: TT) announced today the launch of the Sintesis™ Balance CMAF, a fully electric single unit to heat and cool buildings. The air-cooled multi-pipe solution is the latest model in the Sintesis portfolio of high-performance indoor climate systems by Trane®, the company’s HVAC brand. It is initially available for customers in Europe, Middle East, and Africa.
Sintesis Balance is a fully electric unit that delivers hot and chilled water for heating and cooling. It is ideal for buildings with dynamic temperature requirements, such as schools, hotels, hospitals, retail centers, office buildings and theaters.
“The Sintesis Balance eliminates the need for separate boiler and chiller systems, and provides flexibility to meet comfort needs across climates, seasons, use and occupancy, as well as better use of floor space,” said José La Loggia, president of Trane Technologies’ Commercial HVAC in EMEA. “It also provides highly reliable operation, temperature control and indoor air quality. Most systems in Europe use gas or oil boilers, whereas this solution is fully electric. Since buildings contribute to about 15 percent of global carbon emissions, and heating and cooling represents about 35 percent of that, Sintesis Balance is also a major step on the path to electrification and decarbonization of buildings.”
The innovation contributes to Trane Technologies’ Gigaton Challenge, a goal to reduce customers’ greenhouse gas emissions by a billion metric tons by 2030. The unit recovers and repurposes energy without generating its own carbon emissions, significantly reducing fossil fuel use over typical systems that include both a boiler and a chiller. When drawing from a grid that generates electricity from renewable sources, Sintesis Balance has potential to be a zero-emissions solution.
Sintesis Balance Sustainability by the Numbers
Trane Sintesis Balance has an average Total Efficiency Ratio of 8.2; it generates 8 kW of simultaneous cooling and heating from only 1 kW of electric power. It also delivers a Coefficient of Performance (COP) of 3.35, the highest COP among air-sourced multi-pipe unit options. (COP is a measure of how much heat the system produces per unit of energy input).
The technology’s expanded operating map allows for temperature control even in very hot or cold climates. The heating capabilities of the unit make it a good choice for building applications in regions where ambient air temperatures go down to minus 18 degrees Celsius. The unit also can heat water up to 68 degrees Celsius.
Technical features of the Trane Sintesis Balance CMAF
- Trane Adaptive Refrigerant System™ automatically optimizes refrigerant charge in each operating mode and temperature condition, delivering additional performance and efficiency gains.
- Fully electric driven CMAF multi-pipe unit doesn’t generate direct greenhouse gas emissions beyond emissions from the electricity grid. It offers up to 350 percent higher efficiency compared to most gas boilers when delivering hot water for comfort heating systems.
- Configurability with three acoustic packages and efficiency levels to meet different building application requirements.
- New generation of Trane controls technology – Tracer Symbio™ 800 controller features advanced algorithms ensuring smooth, reliable operation with low cost of ownership. In addition, it also offers six arbitration choices to optimize performances for the application.
- Tracer Symbio 800 with TD7 AdaptiView™ touchscreen provides facility managers with user-friendly control of the unit. The controller allows them to remotely manage and respond to a variety of conditions and maintain efficient operation with various pre-programmed operating modes.
For more details of on the complete Trane portfolio of solutions for EMEA, please visit www.Trane.eu .
About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. Visit tranetechnologies.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200816005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
